Published 19 hours ago • loading... • Updated 19 hours ago

Caliway Biopharmaceuticals Presents Preclinical Research Supporting a Multi-Mechanism Approach to Weight Management at TMASO 2025

Caliway Biopharmaceuticals announced at TMASO 2025 that preclinical data showed combining CBL-514 with tirzepatide produced greater weight and fat reductions than monotherapy.
Amid widespread incretin adoption, scientific sessions highlighted multi-mechanism strategies targeting adipose tissue biology and weight maintenance, with TMASO 2025 participants from Taiwan, Japan and Korea examining obesity management.
Dr. Tzu-Jung Chou presented animal-model data showing CBL-514 targets DYRK1B signaling to increase adipocyte apoptosis and the combination reduced body weight 21.8% vs 14.5% in DIO rat models with post-withdrawal observation.
Caliway said the findings support further clinical investigation of adipocyte-targeted approaches to complement incretin pipelines in combination and maintenance-phase clinical investigation, exploring non-surgical fat reduction, moderate-to-severe cellulite, and weight management.
CBL-514 is positioned as a first-in-class injectable lipolysis agent, described as the world's first to induce adipocyte apoptosis, with 10 clinical trials and 520 subjects completed by May 2025.

Insights by Ground AI

25 Articles

keenesentinel.com

+24 Reposted by 24 other sources

Center

Caliway Biopharmaceuticals Presents Preclinical Research Supporting a Multi-Mechanism Approach to Weight Management at TMASO 2025

Caliway Biopharmaceuticals' preclinical research was highlighted at the 25th Annual Congress of the Taiwan Medical Association for the Study of Obesity, held in conjunction with the 9th Japan-Korea-Taiwan Symposium on Obesity.The animal study explored CBL-514 in combination with a dual…

19 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year